A patient with advanced gastric cancer complicated with liver and lymph node metastases was successfully treated with a novel oral anticancer drug, TS-1, TS-1 was administered at a dose of 100 mg/day. One course consisted of consecutive administration of TS-1 for 28 days and withdrawal for 14 days. At the end of 3 courses a partial response of the liver metastases was achieved. Although the patient has had complications with ascites collection due to hypoalbuminemia, he has been well without regrowth of any metastases for over 8 months.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Helicobacter Pylori-induced BRD2 mA modification sensitizes gastric cancer cells to chemotherapy by breaking FLIP/Caspase-8 homeostasis.
Int J Biol Sci
January 2025
Gastric Cancer Center, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Chemoresistance severely deteriorates the prognosis of advanced gastric cancer (GC) patients. Several studies demonstrated that (HP)-positive GC patients showed better outcomes after receiving chemotherapy than HP-negative ones. This study aims to confirm the role of HP in GC chemotherapy and to study the underlying mechanisms.
View Article and Find Full Text PDFLaparoscopic surgery is associated with increased risk of postoperative peritoneal metastases in T4 colon cancer: a propensity score analysis.
Int J Colorectal Dis
January 2025
Department of Colorectal Surgery, the First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Background: This study aims to evaluate the postoperative safety, long-term survival, and postoperative peritoneal metastases (PPM) rate associated with laparoscopic surgery (LS) for T4 colon cancer.
Materials And Methods: After propensity score matching, there were 68 patients in each of the LS and Open surgery groups. The primary outcomes were the 3-year OS, DFS, and PPM rates.
Two Cases of Colonic Perforation Following Upper Gastrointestinal Barium Examinations.
Cureus
December 2024
Department of Surgery, Kitakyushu City Yahata Hospital, Kitakyushu, JPN.
This report presents two cases of colonic perforation that occurred following an upper gastrointestinal series (UGIS) with barium as part of a health screening. UGIS is a widely performed examination in Japan and is useful for the early detection of gastric cancer and peptic ulcers, but it carries a rare risk of causing serious gastrointestinal perforation. This study details the mechanisms of perforation, risk factors, difficulties in imaging diagnosis, and treatment options.
View Article and Find Full Text PDFPrognostic Impact of Preoperative Left Ventricular Systolic Dysfunction in Older Adult Patients With Gastric Cancer.
In Vivo
December 2024
Division of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Japan.
Background/aim: The effect of left ventricular systolic dysfunction (LVSD), a risk factor for postoperative mortality, in older adult patients with gastric cancer has not been fully elucidated. This study aimed to evaluate the impact of low preoperative left ventricular ejection fraction (EF) on short- and long-term outcomes in older adult patients with gastric cancer.
Patients And Methods: This retrospective study enrolled 237 older adult patients with gastric cancer (≥75 years old) who underwent preoperative echocardiography and curative gastrectomy.
Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403).
Anticancer Res
January 2025
Center for Cancer Genomics and Precision Medicine, Osaka University Hospital, Osaka, Japan.
Article Synopsis
- A study explored salvage chemotherapy using capecitabine plus oxaliplatin (XELOX) for gastric cancer patients who couldn't tolerate or were resistant to cisplatin, but it was halted due to low patient enrollment.
- 12 patients participated, revealing a disease control rate of 90% and a response rate of 30%, with median progression-free survival of 4.2 months and overall survival of 7.1 months.
- Common severe side effects included fatigue and low potassium levels, but there were no treatment-related deaths, suggesting XELOX might be beneficial for these patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!